Given that liver is a major target organ in the CRC malignancy and that the highest expression levels of CCL5, CCR1 and CCR5 were found within liver metastases of human colon cancer patients, we next sought to assess the protective potential of the anti-CCL5 treatment on the development of experimental hepatic metastases into immunocompetent mice. The gene discussed is CCR5; the disease is malignant colon neoplasm.